Reports Q3 revenue $3.65M, consensus $3.7M. Coya‘s CEO Arun Swaminathan, commented, “We believe the Company’s recent financing, which included participation from both new biotech and healthcare institutional investors and existing investors, is a testament to their confidence in our programs; we greatly appreciate their support. With this financing, we anticipate extending our runway into 2H 2027 and past the ALSTARS topline readout.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA:
- Coya Therapeutics price target raised to $17 from $16 at Lake Street
- Coya Therapeutics announces results from COYA 303 in vivo animal study
- Coya Therapeutics’ Promising ALS Study: A Potential Game-Changer?
- Coya Therapeutics Announces Public Offering of Shares
- Coya Therapeutics 3.64M Spot Secondary priced at $5.50